Sodium Flouride

Sodium Fluoride


Avkare
Human Prescription Drug
NDC 42291-741
Sodium Flouride also known as Sodium Fluoride is a human prescription drug labeled by 'Avkare'. National Drug Code (NDC) number for Sodium Flouride is 42291-741. This drug is available in dosage form of Paste, Dentifrice. The names of the active, medicinal ingredients in Sodium Flouride drug includes Sodium Fluoride - 5 mg/mL . The currest status of Sodium Flouride drug is Active.

Drug Information:

Drug NDC: 42291-741
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Flouride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Fluoride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Avkare
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Paste, Dentifrice
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SODIUM FLUORIDE - 5 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:DENTAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 20 Sep, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:AvKARE
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0342291741515
UPC stands for Universal Product Code.
UNII:8ZYQ1474W7
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42291-741-511 TUBE in 1 CARTON (42291-741-51) / 53.2 mL in 1 TUBE20 Sep, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium flouride sodium fluoride water sorbitol spearmint xanthan gum fd&c blue no. 1 sodium benzoate hydrated silica titanium dioxide sodium lauryl sulfate sodium fluoride fluoride ion calcium phosphate, dibasic, anhydrous glycerin xylitol viscous

Indications and Usage:

Indications and usage a dental caries preventive; for once daily self-applied topical use. it is well established that 1.1% sodium fluoride is safe and extraordinarily effective as a caries preventive when applied frequently with mouthpiece applicators.1-4 sodium fluoride 1.1% in a squeeze-tube is easily applied onto a toothbrush. this prescription dental cream should be used once daily in place of your regular toothpaste unless otherwise instructed by your dental professional. may be used whether or not drinking water is fluoridated, since topical fluoride cannot produce fluorosis. (see warnings for exception.)

Warnings:

Warnings prolonged daily ingestion may result in various degrees of dental fluorosis in pediatric patients under age 6 years, especially if the water fluoridation exceeds 0.6 ppm, since younger pediatric patients frequently cannot perform the brushing process without significant swallowing. use in pediatric patients under age 6 years requires special supervision to prevent repeated swallowing of the dental cream which could cause dental fluorosis. read directions carefully before using. keep this product out of the reach of children. in case of accidental overdose, seek professional assistance or contact a poison control center immediately.

General Precautions:

General not for systemic treatment. do not swallow.

Dosage and Administration:

Dosage and administration follow these instructions unless otherwise instructed by your dental professional: 1. adults and pediatric patients 6 years of age or older, apply a thin ribbon of sodium fluoride 1.1% toothpaste to a toothbrush. brush thoroughly once daily for two minutes, preferably at bedtime. 2. after use, adults expectorate. for best results, do not eat, drink, or rinse for 30 minutes. pediatric patients, age 6-16, expectorate after use and rinse mouth thoroughly.

Contraindications:

Contraindications do not use in pediatric patients under age 6 years unless recommended by a dentist or physician.

Adverse Reactions:

Adverse reactions allergic reactions and other idiosyncrasies have been rarely reported. you should call your doctor, or dental professional for medical advise about serious adverse events. to report a serious adverse event or obtain product information, contact avkare at 1-855-361-3993 or fda at 1-800-fda-1088 (toll free).

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category b it has been shown that fluoride crosses the placenta of rats, but only 0.01% of the amount administered is incorporated in fetal tissue. animal studies (rats, mice, rabbits) have shown that fluoride is not a teratogen. maternal exposure to 12.2 mg fluoride/kg of body weight (rats) or 13.1 mg/kg of body weight (rabbits) did not affect the litter size or fetal weight and did not increase the frequency of skeletal or visceral malformations. there are no adequate and well-controlled studies in pregnant women. however, epidemiological studies conducted in areas with high levels of naturally fluoridated water showed no increase in birth defects. heavy exposure to fluoride during in utero development may result in skeletal fluorosis which becomes evident in childhood.

Pediatric Use:

Pediatric use the use of sodium fluoride 1.1% toothpaste in pediatric age groups 6 to 16 years as a caries preventive is supported by pioneering clinical studies with 1.1% sodium fluoride gels in mouth trays in students age 11- 14 years conducted by englander, et al.2,3,4 safety and effectiveness in pediatric patients below the age of 6 years have not been established. please refer to the contraindications and warnings sections.

Geriatric Use:

Geriatric use of the total number of subjects in clinical studies of 1.1% (w/v) sodium fluoride, 15 percent were 65 and over, while 1 percent were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage accidental ingestion of large amounts of fluoride may result in acute burning in the mouth and sore tongue. nausea, vomiting, and diarrhea may occur soon after ingestion (within 30 minutes) and are accompanied by salivation, hematemesis, and epigastric cramping abdominal pain. these symptoms may persist for 24 hours. if less than 5 mg fluoride/kg body weight (i.e., less than 2.3 mg fluoride/lb body weight) have been ingested, give calcium (e.g., milk) orally to relieve gastrointestinal symptoms and observe for a few hours. if more than 5 mg fluoride/kg body weight (i.e., more than 2.3 mg fluoride/lb body weight) have been ingested, induce vomiting, give orally soluble calcium (e.g., milk, 5% calcium gluconate or calcium lactate solution) and immediately seek medical assistance. for accidental ingestion of more than 15 mg fluoride/kg of body weight (i.e., more than 6.9 mg fluoride/lb body weight), induce vomiting and admit immediately to a hospital facility. a treatment dose (a thin ribbon) of sodium fluoride 1.1% toothpaste contains 2.5 mg fluoride. a 1.8 oz. tube contains 255 mg fluoride.

Description:

Description self-topical neutral fluoride dentifrice containing 1.1% (w/w) sodium fluoride for use as a dental caries preventive in adults and pediatric patients. active ingredient sodium fluoride 1.1% (w/w). inactive ingredients dicalcium phosphate, fd&c blue no. 1, flavor, glycerin, hydrated silica, purified water, sodium benzoate, sodium lauryl sulfate, sorbitol, spearmint flavor, titanium dioxide, xanthan gum, xylitol

Clinical Pharmacology:

Clinical pharmacology frequent topical applications to the teeth with preparations having a relatively high fluoride content increase tooth resistance to acid dissolution and enhance penetration of the fluoride ion into tooth enamel.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility in a study conducted in rodents, no carcinogenesis was found in male and female mice and female rats treated with fluoride at dose levels ranging from 4.1 to 9.1 mg/kg of body weight. equivocal evidence of carcinogenesis was reported in male rats treated with 2.5 and 4.1 mg/kg of body weight. in a second study, no carcinogenesis was observed in rats, males or females, treated with fluoride up to 11.3 mg/kg of body weight. epidemiological data provide no credible evidence for an association between fluoride, either naturally occurring or added to drinking water and risk of human cancer. fluoride ion is not mutagenic in standard bacterial systems. it has been shown that fluoride ion has potential to induce chromosome aberrations in cultured human and rodent cells at doses much higher than those to which humans are exposed. in vivo data are conflicting. some studies report chromosome damage in rodents, while other studies using similar
protocols report negative results. potential adverse reproductive effects of fluoride exposure in humans has not been adequately evaluated. adverse effects on reproduction were reported for rats, mice, fox, and cattle exposed to 100 ppm or greater concentrations of fluoride in their diet or drinking water. other studies conducted in rats demonstrated that lower concentrations of fluoride (5 mg/kg of body weight) did not result in impaired fertility and reproductive capabilities.

How Supplied:

How supplied 1.8 oz. (51 g) net wt. tube ndc# 42291-741-51 storage store at controlled room temperature 20° - 25°c (68°-77°f). keep this product out of reach of children rx only

Package Label Principal Display Panel:

Principal display panel - 51 g tube carton 1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.